Beam Therapeutics (BEAM) stock jumps as the company seeks to move gene-editing drug BEAM-302 to pivotal study in.alpha-1 antitrypsin deficiency. Read more here.
Beam to move gene-editing drug in pivotal study (BEAM:NASDAQ)
Beam Therapeutics (BEAM) stock jumps as the company seeks to move gene-editing drug BEAM-302 to pivotal study in.alpha-1 antitrypsin deficiency. Read more here.